Performance data is updated to 30 April 2026.

S&P Biotech ETF

MER · Top 50%AUM · #225 of 293 1Y Return · Top 10%3Y Return · Top 50%5Y Return · #190 of 221

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Link to website

Stock Code

CURE

Fund Manager

Global X

Asset Class

Equities

AUM

$40.36M

MER (%)

0.45%

Listing Date

12/11/2018

Performance (% return)

Investment Focus

Themes

Health

Exposure Regions

World

Portfolio Breakdown

Holdings Breakdown(Top 10 Holdings are 15.11% of total assets)

Company Name	% assets
APELLIS PHARMACE	1.83%
TG THERAPEUTICS	1.71%
TRAVERE THERAPEU	1.61%
REVOLUTION MEDIC	1.60%
ARROWHEAD PHARMA	1.50%
ALKERMES PLC	1.42%
TWIST BIOSCIENCE	1.40%
MADRIGAL PHARMAC	1.39%
BEAM THERAPEUTIC	1.35%
CYTOKINETICS INC	1.30%

Sector	Allocation	% assets
Health Care		100.02%

Similar ETFs

Stock	Name	Fund Manager	AUM $	Listing Date	Asset Class	MER %	1 Year %
DRUG	BetaShares Global Healthcare Currency Hedged ETF	Betashares	$159.16M	08/08/2016	Equities	0.57%	+4.52%

Disclaimer

The information provided on ReviewETF.com.au is intended for general information and comparison purposes only. It is compiled and presented on a best-endeavours basis from publicly available sources, but we do not guarantee its accuracy, completeness, timeliness, or suitability for any particular purpose.

No content on this website constitutes financial advice, investment recommendation, solicitation, or an offer to buy or sell any securities. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of capital.

The point of truth for any ETF is always the official product disclosure statement (PDS), website, and announcements from the ETF issuer/provider (e.g., Vanguard, BetaShares, iShares, VanEck, etc.). We link directly to these primary sources on each individual ETF page wherever possible—please verify all details there before making any decisions.

ReviewETF.com.au, its owner (Joshua), and any associated entities disclaim all liability for any loss or damage arising from the use of, or reliance on, information contained on this site. Users should seek independent professional financial advice tailored to their personal circumstances.

This website may contain links to third-party sites; we are not responsible for their content or privacy practices.

Last updated: January 2026